Search research articles
Contact Us
Filters
Showing results (231-240 of 278) with videos related to
Page
of 28
Sort By:
Cancer
|
November 10, 2020
Associations of baseline patient-reported outcomes with treatment outcomes in advanced gastrointestinal cancer
Emily E van Seventer, Madeleine G Fish, Kathryn Fosbenner, et al.
JCO Precision Oncology
|
August 21, 2018
Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer
Zofia Piotrowska, Mehlika Hazar-Rethinam, Coleen Rizzo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 31, 2018
Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
John Heymach, Lada Krilov, Anthony Alberg, et al.
Cancer Cell
|
December 19, 2012
Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models
Ryan B Corcoran, Katherine A Cheng, Aaron N Hata, et al.
Cancer Discovery
|
October 29, 2013
mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1
Anthony C Faber, Erin M Coffee, Carlotta Costa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 29, 2025
MAPK Pathway Mutations Emerge in Mutant-IDH1 Inhibitor-Resistant Cholangiocarcinoma and Attenuate the Interferon Response
Jinkai Wan, Hatice Duygu Saatcioglu, Haley Ellis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 22, 2018
Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge
C M Parseghian, J M Loree, V K Morris, et al.
The Oncologist
|
August 22, 2020
Revisiting MET: Clinical Characteristics and Treatment Outcomes of Patients with Locally Advanced or Metastatic, MET-Amplified Esophagogastric Cancers
Surendra Pal Chaudhary, Eunice L Kwak, Katie L Hwang, et al.
JCO Oncology Practice
|
May 27, 2021
Care Patterns and Overall Survival in Patients With Early-Onset Metastatic Colorectal Cancer
Katie Kanter, Madeleine Fish, Gianluca Mauri, et al.
Cancer Discovery
|
February 13, 2018
Combined BRAF, EGFR, and MEK Inhibition in Patients with <i>BRAF</i><sup>V600E</sup>-Mutant Colorectal Cancer
Ryan B Corcoran, Thierry André, Chloe E Atreya, et al.
Page
of 28
Search research articles
Search
Showing results (231-240 of 278) with videos related to
Sort By:
Page
of 28
Cancer
|
November 10, 2020
Associations of baseline patient-reported outcomes with treatment outcomes in advanced gastrointestinal cancer
Emily E van Seventer, Madeleine G Fish, Kathryn Fosbenner, et al.
JCO Precision Oncology
|
August 21, 2018
Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer
Zofia Piotrowska, Mehlika Hazar-Rethinam, Coleen Rizzo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 31, 2018
Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
John Heymach, Lada Krilov, Anthony Alberg, et al.
Cancer Cell
|
December 19, 2012
Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models
Ryan B Corcoran, Katherine A Cheng, Aaron N Hata, et al.
Cancer Discovery
|
October 29, 2013
mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1
Anthony C Faber, Erin M Coffee, Carlotta Costa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 29, 2025
MAPK Pathway Mutations Emerge in Mutant-IDH1 Inhibitor-Resistant Cholangiocarcinoma and Attenuate the Interferon Response
Jinkai Wan, Hatice Duygu Saatcioglu, Haley Ellis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 22, 2018
Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge
C M Parseghian, J M Loree, V K Morris, et al.
The Oncologist
|
August 22, 2020
Revisiting MET: Clinical Characteristics and Treatment Outcomes of Patients with Locally Advanced or Metastatic, MET-Amplified Esophagogastric Cancers
Surendra Pal Chaudhary, Eunice L Kwak, Katie L Hwang, et al.
JCO Oncology Practice
|
May 27, 2021
Care Patterns and Overall Survival in Patients With Early-Onset Metastatic Colorectal Cancer
Katie Kanter, Madeleine Fish, Gianluca Mauri, et al.
Cancer Discovery
|
February 13, 2018
Combined BRAF, EGFR, and MEK Inhibition in Patients with <i>BRAF</i><sup>V600E</sup>-Mutant Colorectal Cancer
Ryan B Corcoran, Thierry André, Chloe E Atreya, et al.
Page
of 28